For: | Xue JH, Zhu HH, Wang J, Chen Z. Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C. World J Gastroenterol 2014; 20(23): 7505-7513 [PMID: 24966622 DOI: 10.3748/wjg.v20.i23.7505] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i23/7505.htm |
Number | Citing Articles |
1 |
Zubir S. Rentiya, Matthew Wells, Junun Bae, Kuan-Jen Chen, An-Ning Chao, Nicholas Turgeon, Syed M. Shah, Mostafa Hanout. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257(3): 447 doi: 10.1007/s00417-018-04209-7
|
2 |
A. Rousseau, M. Labetoulle. Effets indésirables oculaires des traitements systémiques : une mise à jour. Journal Français d'Ophtalmologie 2015; 38(9): 876 doi: 10.1016/j.jfo.2015.05.004
|
3 |
Shijie Lan, Zhihua Cui, Qiliang Yin, Zhigang Liu, Lingling Liang, Hua He, Hesong Liu, Zhen Guo, Yingying Yu, Di Wu. Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon α-2b. Melanoma Research 2021; 31(6): 550 doi: 10.1097/CMR.0000000000000769
|
4 |
Bing-Yan Li, Wei Tan, Jing-Ling Zou, Yan He, Shigeo Yoshida, Bing Jiang, Ye-Di Zhou. Role of interferons in diabetic retinopathy. World Journal of Diabetes 2021; 12(7): 939-953 doi: 10.4239/wjd.v12.i7.939
|
5 |
Swathi Somisetty, Ahmad Santina, David Sarraf, William F. Mieler. The Impact of Systemic Medications on Retinal Function. Asia-Pacific Journal of Ophthalmology 2023; 12(2): 115 doi: 10.1097/APO.0000000000000605
|
6 |
Chien‐Hsiung Lai, Yao‐Hsu Yang, Pau‐Chung Chen, Ying‐Chi King, Chia‐Yen Liu. Retinal vascular complications associated with interferon‐ribavirin therapy for chronic hepatitis C: A population‐based study. Pharmacoepidemiology and Drug Safety 2018; 27(2): 191 doi: 10.1002/pds.4363
|
7 |
Chiara Giuffrè, Sara Syed, Sasa Pockar, Jane L Ashworth, Laura R Steeples. Paracentral Acute Middle Maculopathy in A Young Girl Treated with Interferon-Beta for Nasopharyngeal Carcinoma. Ocular Immunology and Inflammation 2023; 31(3): 589 doi: 10.1080/09273948.2022.2032194
|